Loading
TQB2102 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical in phase 3 trials for HR-positive / HER2-negative breast cancer, HER2-positive breast cancer and biliary tract cancer, aimed at HER2.
TQB2102 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical and Chia Tai Tianqing Pharmaceutical. Its target is HER2 (the sponsor names HER2). The sponsor states: Described on the study page as a next-generation HER2 antibody-drug conjugate carrying the small-molecule toxin TQ22723. ClinicalTrials.gov describes the intervention as: TQB2102 is a next-generation HER2 Antibody-Drug Conjugate drug proposed for patients with HER2 positive Recurrent/Metastatic Breast Cancer. It is the investigational product in 8 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07003074 (A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer), NCT06561607 (A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer) and NCT07008976 (Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer), in HR-positive / HER2-negative breast cancer, HER2-positive breast cancer, biliary tract cancer and non-small-cell lung cancer. The largest, NCT07003074, plans to enrol 642 participants with primary completion expected 2029-07. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Described on the study page as a next-generation HER2 antibody-drug conjugate carrying the small-molecule toxin TQ22723. Connects to HER2.
1.TQB2102's antibody arm binds HER2 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"TQB2102" OR ABSTRACT:"TQB2102") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TQB2102, not a curated reading list.
Shares Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors, Sino Biopharmaceutical (Chia Tai Tianqing), HER2, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares HER2, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), HER2-positive breast cancer and the tag pipeline.
Shares Sino Biopharmaceutical (Chia Tai Tianqing), Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer and the tag pipeline.